Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children

New England Journal of Medicine

Volumn 336, Issue 24, 1997, Pages 1704-1712

  Englund, Janet A ^a   Baker, Carol J ^a   Raskino, Claire ^b   Mckinney, Ross E ^c   Petrie, Barbara ^d   Fowler, Mary Glenn ^e   Pearson, Deborah ^f   Gershon, Anne ^g   Mcsherry, George D ^h   Abrams, Elaine J ⁱ   Schliozberg, Jenny ^j   Sullivan, John L ^k   Behrman, Rachel ^l   Connor, James C ^m   Hetherington, Seth ⁿ   Lifschitz, Marta H ^a   McLaren, Colin ^o   Mendez, Herman ^p   Millison, Karen ^q   Moye, Jack ^r   Nozyce, Molly ^s   O'Donnell, Karen ^c   Purdue, Lynette ^e   Schoenfeld, David ^b   Scott, Gwendolynn ^t   Spector, Stephen A ^m   Wara, Diane W ^u   more..

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f UNIVERSITY OF TEXAS   (United States)

^g Och Spine at New York Presbyterian Hospitals   (United States)

^h CHILDREN S HOSPITAL OF NEW JERSEY   (United States)

ⁱ HARLEM HOSPITAL CENTER   (United States)

^j ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^k UNIVERSITY OF MASSACHUSETTS   (United States)

^l CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^m UNIVERSITY OF CALIFORNIA   (United States)

ⁿ GLAXOSMITHKLINE   (United States)

^o BRISTOL MYERS SQUIBB   (United States)

^p SUNY DOWNSTATE MEDICAL CENTER   (United States)

^q ACTG Operations Office   (United States)

^r EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^s BRONX LEBANON HOSPITAL CENTER   (United States)

^t UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^u UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ANTIVIRAL ACTIVITY; ARTICLE; BLOOD TOXICITY; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HUMAN; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; DIDANOSINE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HIV CORE PROTEIN P24; HIV INFECTIONS; HUMANS; INFANT; MALE; TREATMENT OUTCOME; ZIDOVUDINE;

EID: 8244246438     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199706123362403     Document Type: Article

References (21)

1. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994;331:1173-80.
2. Update: AIDS among women -United States, 1994. MMWR Morb Mortal Wkly Rep 1995;44:81-4.
3. Davis SF, Byers RH Jr, Lindegren ML, Caldwell MB, Karon JM, Gwinn M. Prevalence and incidence of vertically acquired HIV infection in the United States. JAMA 1995;274:952-5.
4. Collier AC, Coombs RW, Schoenfeld DA, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med 1996;334:1011-7
5. Butler KM, Husson RN, Balis FM, et al. Dideoxyinosine in children with symptomatic human immunodeficiency virus infection. N Engl J Med 1991;324:137-44.
6. McKinney RE Jr, Maha MA, Connor EM, et al. A multicenter trial of oral zidovudine in children with advanced human immunodeficiency virus disease. N Engl J Med 1991;324:1018-25.
7. McKinney RE Jr, Wilfert C, AIDS Clinical Trials Group Protocol 043 Study Group. Growth as a prognostic indicator in children with human immunodeficiency virus infection treated with zidovudine. J Pediatr 1994; 125:728-33.
8. Ogino MT, Dankner WM, Spector SA. Development and significance of zidovudine resistance in children infected with human immunodeficiency virus. J Pediatr 1993;123:1-8.
9. Mueller BU, Butler KM, Stocker VL, et al. Clinical and pharmacokinetic evaluation of long-term therapy with didanosine in children with HIV infection. Pediatrics 1994;94:724-31.
10. Englund JA, Baker CJ, Raskino C, et al. Clinical and laboratory characteristics of a large cohort of symptomatic, human immunodeficiency virus-infected infants and children. Pediatr Infect Dis J 1996;15:1025-36.
11. Roche AF, Himes JH. Incremental growth charts. Am J Clin Nutr 1980;33:2041-52.
12. Brady MT, McGrath N, Brouwers P, et al. Randomized study of the tolerance and efficacy of high- versus low-dose zidovudine in human immunodeficiency virus-infected children with mild to moderate symptoms (AIDS Clinical Trials Group 128). J Infect Dis 1996;173:1097-106.
13. Altman DG. Practical statistics for medical research. London: Chapman & Hall, 1991.
14. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: John Wiley, 1980.
15. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979;35:549-56.
16. Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983;70:659-63.
17. Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996;335:1081-90.
18. Delta Coordinating Committee. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996;348:283-91.
19. Balis FM, Pizzo PA, Murphy RF, et al. The pharmacokinetics of zidovudine administered by continuous infusion in children. Ann Intern Med 1989;110:279-85.
20. Mueller BU, Zuckerman J, Nelson RP Jr, et al. Update on the pediatric phase I/II study of the protease inhibitor ritonavir (ABT-538). Presented at the 4th Conference on Retroviruses and Opportunistic Infections, Washington, D.C., January 25, 1997 abstract.
21. Luzuriaga K, Bryson Y, Krogstad P, et al. Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection. N Engl J Med 1997;336:1343-9.